Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Launched by JUNO THERAPEUTICS, INC., A BRISTOL-MYERS SQUIBB COMPANY · Feb 28, 2024
Trial Information
Current as of November 02, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called BMS-986393, which is a type of CAR T cell therapy aimed at helping adults with relapsed or refractory multiple myeloma. This means it is designed for patients whose multiple myeloma has come back or has not responded to previous treatments. The trial will look at how well this therapy works and how safe it is for patients.
To participate, patients need to be between the ages of 65 and 74 and must have a confirmed diagnosis of multiple myeloma. They should have already tried at least four different treatment types and have experienced disease progression after their last treatment. Participants will be monitored closely and can expect to undergo certain tests to measure their disease during the trial. It's important to know that patients with certain health conditions or previous treatments related to this study may not be eligible. Overall, this trial aims to find a new option for those struggling with this challenging cancer.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
- • Received at least 3 classes of MM treatment \[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and at least 3 prior lines of therapy (LOT).
- • Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
- • Participants must have measurable disease during screening.
- • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- • Exclusion Criteria
- • Active or history of central nervous system involvement with MM.
- • Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
- • Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.
- • Other protocol-defined Inclusion/Exclusion criteria apply.
About Juno Therapeutics, Inc., A Bristol Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb company, is a biopharmaceutical organization dedicated to advancing innovative cell therapies for the treatment of cancer. With a strong focus on harnessing the power of the immune system, Juno is at the forefront of developing cutting-edge therapies, including CAR T-cell and TCR therapies, aimed at addressing unmet medical needs in hematologic malignancies and solid tumors. As a leader in the field of immuno-oncology, Juno Therapeutics combines rigorous scientific research with a commitment to patient-centric solutions, striving to improve outcomes for patients battling cancer worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Boston, Massachusetts, United States
Birmingham, Alabama, United States
Iowa City, Iowa, United States
Buffalo, New York, United States
Saint Louis, Missouri, United States
Chicago, Illinois, United States
Salt Lake City, Utah, United States
Little Rock, Arkansas, United States
New York, New York, United States
Atlanta, Georgia, United States
Tampa, Florida, United States
Boston, Massachusetts, United States
Birmingham, Alabama, United States
New Brunswick, New Jersey, United States
Jacksonville, Florida, United States
Nashville, Tennessee, United States
Portland, Oregon, United States
Chicago, Illinois, United States
Dallas, Texas, United States
Houston, Texas, United States
Pittsburgh, Pennsylvania, United States
New York, New York, United States
Norfolk, Virginia, United States
Seattle, Washington, United States
Calgary, Alberta, Canada
Atlanta, Georgia, United States
Denver, Colorado, United States
Charlottesville, Virginia, United States
Nashville, Tennessee, United States
Cincinnati, Ohio, United States
Tokyo, Japan
Chiba, Japan
Evanston, Illinois, United States
Chapel Hill, North Carolina, United States
New Brunswick, New Jersey, United States
Kyoto, Japan
Gilbert, Arizona, United States
Montréal, Quebec, Canada
Saint Louis, Missouri, United States
Louisville, Kentucky, United States
New York, New York, United States
Chicago, Illinois, United States
Miami, Florida, United States
Rochester, Minnesota, United States
Atlanta, Georgia, United States
Madison, Wisconsin, United States
San Francisco, California, United States
Nishinomiya, Hyogo, Japan
Westwood, Kansas, United States
Nashville, Tennessee, United States
Camperdown, New South Wales, Australia
Columbus, Ohio, United States
Nashville, Tennessee, United States
Birmingham, Alabama, United States
Portland, Oregon, United States
Atlanta, Georgia, United States
Saint Matthews, Kentucky, United States
San Antonio, Texas, United States
Madison, Wisconsin, United States
Calgary, Alberta, Canada
Montréal, Quebec, Canada
Nagoya, Japan
Gilbert, Arizona, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
San Francisco, California, United States
Miami, Florida, United States
Tampa, Florida, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Kansas City, Kansas, United States
Saint Matthews, Kentucky, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Rochester, Minnesota, United States
New Brunswick, New Jersey, United States
Buffalo, New York, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Seattle, Washington, United States
Westwood, Kansas, United States
Jacksonville, Florida, United States
Dallas, Texas, United States
Nagoya, Aichi, Japan
Nishinomiya, Hyogo, Japan
Chiba, Japan
Kyoto, Japan
Tokyo, Japan
Boston, Massachusetts, United States
Baltimore, Maryland, United States
Charlotte, North Carolina, United States
Austin, Texas, United States
Norfolk, Virginia, United States
Calgary, Alberta, Canada
Philadelphia, Pennsylvania, United States
Brisbane, Queensland, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported